[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2014250643B2 - Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate - Google Patents

Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate

Info

Publication number
AU2014250643B2
AU2014250643B2 AU2014250643A AU2014250643A AU2014250643B2 AU 2014250643 B2 AU2014250643 B2 AU 2014250643B2 AU 2014250643 A AU2014250643 A AU 2014250643A AU 2014250643 A AU2014250643 A AU 2014250643A AU 2014250643 B2 AU2014250643 B2 AU 2014250643B2
Authority
AU
Australia
Prior art keywords
liver function
restoration
treatment
portal hypertension
ornithine phenylacetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014250643A
Other versions
AU2014250643A1 (en
Inventor
Keith Anderson
Rajiv Jalan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Ocera Therapeutics Inc
Original Assignee
UCL Business Ltd
Ocera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010258888A external-priority patent/AU2010258888B2/en
Application filed by UCL Business Ltd, Ocera Therapeutics Inc filed Critical UCL Business Ltd
Priority to AU2014250643A priority Critical patent/AU2014250643B2/en
Publication of AU2014250643A1 publication Critical patent/AU2014250643A1/en
Application granted granted Critical
Publication of AU2014250643B2 publication Critical patent/AU2014250643B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

TREATMENT OF PORTAL HYPERTENSION AND RESTORATION OF LIVER FUNCTION USING L-ORNITHINE PHENYLACETATE Disclosed herein are methods of treating and/or preventing portal hypertension and/or restoring liver function using L-ornithine phenylacetate.
AU2014250643A 2009-06-08 2014-10-15 Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate Active AU2014250643B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014250643A AU2014250643B2 (en) 2009-06-08 2014-10-15 Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US61/185,158 2009-06-08
US61/240,748 2009-09-09
US61/296,377 2010-01-19
AU2010258888A AU2010258888B2 (en) 2009-06-08 2010-06-08 Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
AU2014250643A AU2014250643B2 (en) 2009-06-08 2014-10-15 Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2010258888A Division AU2010258888B2 (en) 2009-06-08 2010-06-08 Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate

Publications (2)

Publication Number Publication Date
AU2014250643A1 AU2014250643A1 (en) 2014-11-06
AU2014250643B2 true AU2014250643B2 (en) 2016-07-14

Family

ID=51845146

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014250643A Active AU2014250643B2 (en) 2009-06-08 2014-10-15 Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate

Country Status (1)

Country Link
AU (1) AU2014250643B2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1824563T3 (en) 2004-11-26 2010-05-31 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for the treatment of hepatic encephalopathy
CA2998434C (en) 2009-04-03 2020-05-12 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
EP3517110A1 (en) 2009-06-08 2019-07-31 UCL Business PLC Treatment of inflammation using l-ornithine phenylacetate
IL281349B (en) 2014-11-24 2022-09-01 Ucl Business Ltd Treatment of diseases related to hepatic stellate cell activity using ammonia-lowering treatments
EP4205735A1 (en) * 2015-04-20 2023-07-05 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
HK1249434A1 (en) 2015-08-18 2018-11-02 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
KR20250023993A (en) 2015-11-13 2025-02-18 오세라 테라퓨틱스, 아이엔씨. Formulation of l-ornithine phenylacetate
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
CN110740988A (en) 2017-05-11 2020-01-31 欧塞拉治疗有限公司 Method for preparing L-ornithine phenylacetate

Also Published As

Publication number Publication date
AU2014250643A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
MX2020009703A (en) Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate.
AU2014250643B2 (en) Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
PH12017500930A1 (en) Hsp90 inhibitor combinations
WO2009111676A8 (en) Boron-containing small molecules as anti-inflammatory agents
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
MX2010009765A (en) Boron-containing small molecules as anti-inflammatory agents.
BR112012018761A2 (en) structures to prevent microorganism fixation
MX369788B (en) Targeted modification of malate dehydrogenase.
MY163031A (en) Method of treating obesity using antioxidant inflammation modulators
WO2009099719A3 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
MX2010005395A (en) Method of treating arthritis.
MX349886B (en) Anti-pseudomonas psl binding molecules and uses thereof.
WO2011100295A3 (en) Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase
WO2012073047A3 (en) Compositions and methods
MX341340B (en) Flame treatment of a substrate.
WO2012074725A3 (en) Immunomodulatory methods and systems for treatment and/or prevention of hypertension
EP2597949A4 (en) Sub-micron compositions
AU2010298020A8 (en) Combination
TN2011000214A1 (en) Combination of hsp90 and herceptin inhibitors
WO2011116351A3 (en) Methods and compositions for the treatment of cancer
WO2011110367A3 (en) Method of screening for htra protease inhibitors useful for prophylaxis and therapy of a bacterial infection
WO2009100445A3 (en) Compositions and methods which modulate g-protein signaling for the treatment of asthma
WO2011006097A3 (en) Methods For Treating Toxicity
WO2012051165A3 (en) Mir-211 expression and related pathways in human melanoma
AU2015201137B2 (en) Compositions and method for tissue preservation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)